DIRAS3抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P00958(DIRAS3 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P00958(DIRAS3 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

DIRAS3. also known as ARHI or NOEY2. is a maternally imprinted tumor suppressor gene belonging to the RAS GTPase superfamily. Unlike most RAS family members that promote tumor growth, DIRAS3 acts as a negative regulator of cell proliferation, survival, and metastasis. It is expressed in normal ovarian, breast, and thyroid tissues but frequently downregulated or silenced in cancers through mechanisms like promoter methylation, loss of heterozygosity, or transcriptional repression. DIRAS3 modulates key pathways including PI3K/AKT/mTOR, STAT3. and autophagy, making it a critical player in cancer biology and potential therapeutic target.

DIRAS3 antibodies are essential tools for studying its expression patterns, epigenetic regulation, and functional roles in tumorigenesis. These antibodies enable detection of endogenous DIRAS3 protein via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Researchers use them to investigate DIRAS3's tumor-suppressive effects in preclinical models and evaluate its clinical relevance through correlation studies with patient survival, drug resistance, or metastasis. Some antibodies specifically recognize unique epitopes within the N-terminal extension that distinguishes DIRAS3 from other RAS proteins. Validation parameters include reactivity with DIRAS3-overexpressing cell lines and loss of signal in DIRAS3-knockdown models. Commercial DIRAS3 antibodies are typically developed in rabbit or mouse hosts, available as monoclonal or polyclonal formats, with applications spanning basic research to diagnostic biomarker development.